A Phase 2B/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritis Relief Through Itch Scratch Modulation (PRISM Study)

Main inclusion criteria:

  1. Individuals diagnosed with generalized PN, defined as the presence of ≥ 10 pruriginous nodules, involving at least 2 distinct anatomical areas: for example, either 2 limbs; or a single limb and some axial portion of the body.
  2. If there is any history of a primary pruritic skin condition other than PN, that condition must have been inactive for at least 6 months prior to screening.

 

Principal Investigator(s)
Dr. Jonathan Silverberg
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

8 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.